NCT03703791 is a Phase 3 clinical trial of AR101 in Peanut Allergy, sponsored by Aimmune Therapeutics, Inc..

Who is sponsoring NCT03703791?

NCT03703791 is sponsored by Aimmune Therapeutics, Inc..

What drugs are being tested in NCT03703791?

Interventions in NCT03703791: AR101.

What condition does NCT03703791 study?

NCT03703791 studies Peanut Allergy.

Is NCT03703791 still recruiting?

NCT03703791 is currently terminated. Last updated 13 July 2021.

Are results published for NCT03703791?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-07-13 · How we verify

NCT03703791

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents

Terminated Phase 3 Results posted Last updated 13 July 2021

What this trial tests

Phase 3 trial testing AR101 in Peanut Allergy in 1 participant. Terminated before completion.

Timeline

24 October 2018

Primary endpoint
23 November 2018

23 November 2018

Quick facts

Lead sponsor	Aimmune Therapeutics, Inc.
Phase	Phase 3
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	1
Start date	24 October 2018
Primary completion	23 November 2018
Estimated completion	23 November 2018
Sites	11 locations across Spain

Drugs / interventions tested

AR101 — full drug profile →

Conditions studied

Peanut Allergy — all drugs for Peanut Allergy →

Sponsor

Aimmune Therapeutics, Inc. — full company profile →

Who can join

Adults 4 to 17, any sex, with Peanut Allergy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To compare the HRQOL of AR101 characterized oral desensitization immunotherapy (CODIT™) in combination with standard of care (peanut avoidance, education) versus standard of care alone in peanut-allergic subjects aged 4 to 17 years.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of AR101

Trials testing the same drug.

NCT03682770 — Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut · Phase 2 · completed
NCT03292484 — Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008) · Phase 3 · completed
NCT03337542 — AR101 Real-World Open-Label Extension Study · Phase 3 · completed
NCT03126227 — Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES) · Phase 3 · completed
NCT02993107 — PALISADE Follow-on Study (ARC004) · Phase 3 · completed

Other recruiting trials for Peanut Allergy

Currently open trials in the same condition.

NCT07349212 — UKK-0018 as an Immunotherapeutic for Treatment of Peanut Allergies · Phase 1, PHASE2 · recruiting
NCT05695261 — Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients · Phase 2 · recruiting
NCT05503446 — Using Commonly Available Food Products To Treat Food Allergy · NA · active not recruiting
NCT05667610 — Immune-supportive Diet and Gut Permeability in Allergic Children · NA · recruiting
NCT06256146 — Investigating Modified Protocols of Oral Immunotherapy to Validate Efficacy and Safety · NA · recruiting

Other Aimmune Therapeutics, Inc. trials

Trials by the same sponsor.

NCT04056299 — Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy · Phase 2 · terminated
NCT03736447 — Peanut Oral Immunotherapy Study of Early Intervention for Desensitization · Phase 3 · completed
NCT03292484 — Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008) · Phase 3 · completed
NCT03337542 — AR101 Real-World Open-Label Extension Study · Phase 3 · completed
NCT03201003 — ARTEMIS Peanut Allergy In Children · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03703791 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Aimmune Therapeutics, Inc.
Last refreshed: 13 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03703791.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing